Optimizing Outcomes: Bevacizumab with Carboplatin and Paclitaxel in 5110 Ovarian Cancer Patients-A Systematic Review and Meta-Analysis.
Yu Jin KimHee Min LeeGa Eun LeeJin Hui YooHwa Jeong LeeSandy Jeong Yeon RhiePublished in: Pharmaceuticals (Basel, Switzerland) (2024)
The combination of carboplatin, paclitaxel, and bevacizumab improves PFS compared to the regimen without bevacizumab, but it raises significant safety concerns. Clinical management should consider adverse event prevention by vigilantly monitoring blood pressure, signs and symptoms of bleeding, thromboembolism, GI perforation, and pain to balance the therapeutic benefits with the potential risks of this combination therapy.
Keyphrases
- combination therapy
- blood pressure
- end stage renal disease
- metastatic colorectal cancer
- newly diagnosed
- ejection fraction
- phase ii study
- chronic kidney disease
- peritoneal dialysis
- human health
- prognostic factors
- chronic pain
- atrial fibrillation
- heart rate
- pain management
- risk assessment
- phase iii
- radiation therapy
- spinal cord injury
- sleep quality
- climate change
- patient reported outcomes
- glycemic control
- adverse drug